Business · Companies · 2 hrs ago

Johnson & Johnson considers buying Ollin Biosciences for up to $3.4bn

Johnson & Johnson considers buying Ollin Biosciences for up to $3.4bn

Johnson & Johnson is looking to buy Ollin Biosciences in a potential deal worth up to $3.4bn.

Ollin is a biotechnology company focused on eye disease, according to the available details.

The proposed acquisition is part of a recent surge in biotech deals.

The deal would bring the eye-disease company under the ownership of the drugmaker if completed.

The potential price is as much as $3.4bn, but no lower figure is given.

The acquisition has not been described as completed, and no further steps are specified.

1 source

Related